Is Dual Antiplatherpy a Good Choice for Primary Patency?

The duel antiplati group was younger, but they were more complex medical and atho schlerotic disease patterns. After adjusting for these pre operative demographic and inter operative technical factors, analysis did not show any difference between the dual anti platelet and asperon cohorts. But on sub group analysis based on bipast conduit, dual antiplattherapy was found to have a protective effect on patency only in the prosthetic bi past cohort. Long term bleeding risk is unable to be evaluated in v c i, as is not one of the data points that's collected.